Research map: Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting

Back to the article

Papers in this map

  1. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms · Sowmya Parampalli Yajnanarayana · 2015 · 166 citations · Cited by this paper
  2. Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation · 2026 · Related
  3. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera · Marina Kremyanskaya · 2024 · 56 citations · Cited by this paper
  4. Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications · 2026 · Related
  5. Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies · John Mascarenhas · 2025 · 11 citations · Cited by this paper
  6. Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML · 2026 · Related
  7. Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia · Vikas Gupta · 2025 · 10 citations · Cited by this paper
  8. Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma · 2026 · Related
  9. Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study · Raajit K. Rampal · 2025 · 6 citations · Cited by this paper
  10. Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting · 2026 · Related
  11. Evaluation of the novel TMPRSS6 antisense inhibitor sapablursen for treatment of polycythemia vera: Results of the imprssion clinical trial · Jeanne M. Palmer · 2025 · 4 citations · Cited by this paper
  12. Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma · 2026 · Related
  13. Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study · Andrew Tucker Kuykendall · 2025 · 3 citations · Cited by this paper
  14. Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types · 2026 · Related
  15. Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells · Bethan Psaila · 2025 · 3 citations · Cited by this paper
  16. Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy · 2026 · Related
  17. Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis · John O Mascarenhas · 2025 · 2 citations · Cited by this paper
  18. Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer · 2026 · Related
  19. Long-term rusfertide treatment in polycythemia vera: Initial results from the phase 2 THRIVE extension study · Naveen Pemmaraju · 2025 · 2 citations · Cited by this paper
  20. Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy · 2026 · Related
  21. Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study · David M. Ross · 2025 · 1 citation · Cited by this paper
  22. Should dermatologic examinations become routine standard of care in patients with polycythemia vera? Observations from the phase 3 VERIFY study prior to rusfertide exposure · Joseph James Shatzel · 2025 · 1 citation · Cited by this paper
  23. Efficacy and safety of ruxolitinib-based combination therapy in the patients with myelofibrosis (MF): A systematic review and meta-analysis · Shuai Tan · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)